







**Press Release**

**Cipla announces Q2 FY 1213 Unaudited Financial Results**

**Mumbai, India, 5th November 2012:** Cipla Limited (BSE: 500087, NSE : CIPLA) today announced its Unaudited Financial Results for the quarter ended September 30, 2012 (Q2).

**Key Financial & Performance Highlights Q2 FY1213 vis-a-vis Q2 FY1112:**

- Gross revenues grew by 23.6% to Rs. 2220 cr, up from Rs. 1796 cr in Q2 FY1112
- Operating margins grew by 57.7% to Rs. 677 cr, up from Rs. 429 cr in Q2 FY1112
- Profit after tax grew by 61.8% to Rs. 500 cr during Q2 FY1213, up from Rs. 309 cr (Q2 FY1112)



### **Profit & Loss Highlights:**

- Material cost at 36.3% of Total Sales decreased by 4.2% during Q2 FY1213 as compared to Q2 FY1112.
- Operating margins increased by 57.7% and is at 30.5% of Income from Operations during Q2 FY1213 as compared to 23.9% during Q2 FY1112.
- Profit after tax increased by 61.8% to Rs. 500 cr during Q2 FY1213 as compared to Rs. 309 cr during Q2 FY1112.

### **Performance Review:**

#### ***Domestic business:***

- Domestic revenues grew by 13.5% to Rs.962 cr during Q2 FY1213, up from Rs. 847 cr during Q2 FY1112.
- The growth in domestic revenues was largely on account of growth in anti-asthma, anti-biotics and cardiovascular therapy segments.

#### ***International business:***

- Exports of formulations grew by 38.2% to Rs. 1039 cr during Q2 FY1213, up from Rs. 752 cr during Q2 FY1112.
- Exports of APIs grew by 9.0% to Rs. 174 cr during Q2 FY1213, from Rs. 159 cr during Q2 FY1112.
- The growth in export revenues was primarily due to growth in anti-depressants, anti-ulcerant and anti-asthma segments.

### **About Cipla:**

Cipla laid foundations for the Indian pharmaceutical industry back in 1935 with the vision to make India self-reliant in healthcare. Over the years Cipla has emerged as one of the most respected names not just in India but worldwide. Its state of the art R&D centre has given the country and the world many firsts. This includes the revolutionary AIDS cocktail for less than a dollar a day. With over 34 manufacturing units across the country, Cipla manufactures over 2000 products in 65 therapies.

With a turnover of over US \$ 1.4 billion, Cipla serves doctors and patients in over 170 countries. It has earned a name for maintaining one global standard across all its products and services. Cipla continues to support, improve and save millions of lives with its high-quality drugs and innovative devices. ([www.cipla.com](http://www.cipla.com)).

### **Media Contact:**

#### **Finance**

Ajay Luharuka

Contact No.: 022 – 23025435

E-Mail: [ajay@cipla.com](mailto:ajay@cipla.com)

#### **Corporate Communications**

Antara Mukherjee

Contact No.: 022 – 23025810

E-Mail: [antara.mukherjee@cipla.com](mailto:antara.mukherjee@cipla.com)

Jaisingh Balakrishnan

Contact No.: 022 - 23025813

E Mail: [jaisingh.krishnan@cipla.com](mailto:jaisingh.krishnan@cipla.com)